FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385361308> ?p ?o ?g. }

• W4385361308 abstract "Background The alkaloid camptothecin analog SN38 is a potent antineoplastic agent, but cannot be used directly for clinical application due to its poor water solubility. Currently, the prodrug approach on SN38 has resulted in 3 FDA-approved cancer therapeutics, irinotecan, ONIVYDE, and Trodelvy. However, only 2-8% of irinotecan can be transformed enzymatically in vivo into the active metabolite SN38, which severely limits the drug's efficacy. While numerous drug delivery systems have been attempted to achieve effective SN38 delivery, none have produced drug products with antitumor efficacy better than irinotecan in clinical trials. Therefore, novel approaches are urgently needed for effectively delivering SN38 to cancer cells with better efficacy and lower toxicity. Methods Based on the unique properties of human serum albumin (HSA), we have developed a novel single protein encapsulation (SPE) technology to formulate cancer therapeutics for improving their pharmacokinetics (PK) and antitumor efficacy and reducing their side effects. Previous application of SPE technology to doxorubicin (DOX) formulation has led to a promising drug candidate SPEDOX-6 (FDA IND #, 152154), which will undergo a human phase I clinical trial. Using the same SPE platform on SN38, we have now produced two SPESN38 complexes, SPESN38-5 and SPESN38-8. We conducted their pharmacological evaluations with respect to maximum tolerated dose, PK, and in vivo efficacy against colorectal cancer (CRC) and soft tissue sarcoma (STS) in mouse models. Results The lyophilized SPESN38 complexes can dissolve in aqueous media to form clear and stable solutions. Maximum tolerated dose (MTD) of SPESN38-5 is 250 mg/kg by oral route (PO) and 55 mg/kg by intravenous route (IV) in CD-1 mice. SPESN38-8 has the MTD of 45 mg/kg by IV in the same mouse model. PK of SPESN38-5 by PO at 250 mg/kg gave mouse plasma AUC 0-∞ of 0.0548 and 4.5007 (nmol x h/mL) for SN38 and SN38 glucuronidate (SN38G), respectively, with a surprisingly high molar ratio of SN38G:SN38 = 82:1. However, PK of SPESN38-5 by IV at 55 mg/kg yielded much higher mouse plasma AUC 0-∞ of 18.80 and 27.78 nmol x h/mL for SN38 and SN38G, producing a much lower molar ratio of SN38G:SN38 = 1.48:1. Antitumor efficacy of SPESN38-5 and irinotecan (control) was evaluated against HCT-116 CRC xenograft tumors. The data indicates that SPESN38-5 by IV at 55 mg/kg is more effective in suppressing HCT-116 tumor growth with lower systemic toxicity compared to irinotecan at 50 mg/kg. Additionally, SPESN38-8 and DOX (control) by IV were evaluated in the SK-LMS-1 STS mouse model. The results show that SPESN38-8 at 33 mg/kg is highly effective for inhibiting SK-LMS-1 tumor growth with low toxicity, in contrast to DOX's insensitivity to SK-LMS-1 with high toxicity. Conclusion SPESN38 complexes provide a water soluble SN38 formulation. SPESN38-5 and SPESN38-8 demonstrate better PK values, lower toxicity, and superior antitumor efficacy in mouse models, compared with irinotecan and DOX." @default.
• W4385361308 created "2023-07-29" @default.
• W4385361308 creator A5003315806 @default.
• W4385361308 creator A5005685949 @default.
• W4385361308 creator A5010902953 @default.
• W4385361308 creator A5021456840 @default.
• W4385361308 creator A5027674029 @default.
• W4385361308 creator A5029609547 @default.
• W4385361308 creator A5052275329 @default.
• W4385361308 creator A5059734562 @default.
• W4385361308 creator A5062083547 @default.
• W4385361308 creator A5065200631 @default.
• W4385361308 creator A5074046007 @default.
• W4385361308 date "2023-07-27" @default.
• W4385361308 modified "2023-09-27" @default.
• W4385361308 title "Single Protein Encapsulated SN38 for Tumor-Targeting Treatment" @default.
• W4385361308 cites W1502025781 @default.
• W4385361308 cites W1522093588 @default.
• W4385361308 cites W1549846058 @default.
• W4385361308 cites W1586224276 @default.
• W4385361308 cites W1593461257 @default.
• W4385361308 cites W1777256341 @default.
• W4385361308 cites W1871475547 @default.
• W4385361308 cites W1965278354 @default.
• W4385361308 cites W1970179483 @default.
• W4385361308 cites W1975616471 @default.
• W4385361308 cites W1985006418 @default.
• W4385361308 cites W1985089491 @default.
• W4385361308 cites W1986896123 @default.
• W4385361308 cites W2000930736 @default.
• W4385361308 cites W2013319406 @default.
• W4385361308 cites W2016722642 @default.
• W4385361308 cites W2017688681 @default.
• W4385361308 cites W2020721911 @default.
• W4385361308 cites W2031733136 @default.
• W4385361308 cites W2032757862 @default.
• W4385361308 cites W2032894521 @default.
• W4385361308 cites W2038692006 @default.
• W4385361308 cites W2043398720 @default.
• W4385361308 cites W2051318720 @default.
• W4385361308 cites W2059496782 @default.
• W4385361308 cites W2060336321 @default.
• W4385361308 cites W2067258739 @default.
• W4385361308 cites W2085901921 @default.
• W4385361308 cites W2086179083 @default.
• W4385361308 cites W2088895925 @default.
• W4385361308 cites W2092938559 @default.
• W4385361308 cites W2094864265 @default.
• W4385361308 cites W2122517878 @default.
• W4385361308 cites W2126350892 @default.
• W4385361308 cites W2127401827 @default.
• W4385361308 cites W2127843578 @default.
• W4385361308 cites W2146274229 @default.
• W4385361308 cites W2162472950 @default.
• W4385361308 cites W2222212459 @default.
• W4385361308 cites W2246769930 @default.
• W4385361308 cites W2261898534 @default.
• W4385361308 cites W2265208154 @default.
• W4385361308 cites W2317936438 @default.
• W4385361308 cites W2333871875 @default.
• W4385361308 cites W2336436649 @default.
• W4385361308 cites W2429529028 @default.
• W4385361308 cites W2438328170 @default.
• W4385361308 cites W2443738381 @default.
• W4385361308 cites W2545902480 @default.
• W4385361308 cites W2560018831 @default.
• W4385361308 cites W2564262333 @default.
• W4385361308 cites W2589575011 @default.
• W4385361308 cites W2595666038 @default.
• W4385361308 cites W2607129810 @default.
• W4385361308 cites W2755462565 @default.
• W4385361308 cites W2790768119 @default.
• W4385361308 cites W2800041021 @default.
• W4385361308 cites W2809072147 @default.
• W4385361308 cites W2883860383 @default.
• W4385361308 cites W2895472244 @default.
• W4385361308 cites W2909488740 @default.
• W4385361308 cites W2909729333 @default.
• W4385361308 cites W2982223252 @default.
• W4385361308 cites W3023499671 @default.
• W4385361308 cites W3041813955 @default.
• W4385361308 cites W3093222476 @default.
• W4385361308 cites W3108675365 @default.
• W4385361308 cites W3156985612 @default.
• W4385361308 cites W3181934877 @default.
• W4385361308 cites W3213334042 @default.
• W4385361308 cites W4220659921 @default.
• W4385361308 cites W4224277044 @default.
• W4385361308 cites W613390919 @default.
• W4385361308 doi "https://doi.org/10.21203/rs.3.rs-3154635/v1" @default.
• W4385361308 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37546894" @default.
• W4385361308 hasPublicationYear "2023" @default.
• W4385361308 type Work @default.
• W4385361308 citedByCount "0" @default.
• W4385361308 crossrefType "posted-content" @default.
• W4385361308 hasAuthorship W4385361308A5003315806 @default.
• W4385361308 hasAuthorship W4385361308A5005685949 @default.
• W4385361308 hasAuthorship W4385361308A5010902953 @default.
• W4385361308 hasAuthorship W4385361308A5021456840 @default.
• W4385361308 hasAuthorship W4385361308A5027674029 @default.

• next